US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MATTHEWS EMERGING MARKETS DISCOVERY ACTIVE ETF

30.19

-0.5144-1.68%

Post-market: 30.700.5144+1.70%16:10 EDT

Volume:181

Turnover:5K

Market Cap:21.74M

PE:- -

High:30.19

Open:30.70

Low:30.19

Close:30.70

52wk High:32.57

52wk Low:24.64

Shares:720.00K

Float Shares:720.00K

Volume Ratio:0.35

T/O Rate:0.03%

Dividend:0.72

Dividend Rate:2.37%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Two Ministries Unveil 30 Trillion Yuan Plan to Supercharge Electronics Manufacturing

Legend Biotech Updates and Expands Cell Therapy Clinical Pipeline

Legend Biotech : Barclays Cuts Target Price to $74 from $78

THOMSON REUTERS

GenScript Unit Legend Biotech to Present Updated Long-Term Carvykti Cartitude-2 Data at IMS Meeting

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

MEMSCAP lifts first-half profit 53% and pays inaugural dividend

MEMSCAP to Host Investor Webcast on First‑Half 2026 Results

Will Legend Biotech’s (LEGN) Move to Q2 Profitability Reshape Its Investment Narrative?

Simply Wall St.

Legend Biotech (LEGN) Turns Profitable In Q2, Is The Stock Cheap?

Simply Wall St.

Legend Biotech Sets September 24, 2026 AGM With Expanded Equity Plan on Agenda

Legend Biotech Seeks Shareholder OK to Add 19.1 Million Shares to RSU Plan Reserve

Legend Biotech Announces Annual General Meeting

How Legend Biotech’s Q2 Profitability Jump and Interim CEO Shift Will Impact Legend Biotech (LEGN) Investors

Simply Wall St.

Celcuity Posts Narrower-than-Expected Loss as R&D Costs Decreased

CorMedix Beats Q2 Revenue Estimates on DefenCath Growth, Raises FY Adjusted Ebitda Guidance

Oncology Device Maker RenovoRx's Q2 Revenue Surges, Raises FY Outlook

MaxCyte Q2 Revenue Beats Estimates

Kura Oncology Q2 Product Revenue Rises 57% on Komzifti Uptake

Sector Update: Healthcare Stocks Advance Late Afternoon

MT Newswires Live

Legend Biotech Could See Pressures From Competition, CEO Transition, Oppenheimer Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/MEMS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MEMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEMS\",,,,,undefined,":{"symbol":"MEMS","market":"US","secType":"STK","nameCN":"MATTHEWS EMERGING MARKETS DISCOVERY ACTIVE ETF","latestPrice":30.1889,"timestamp":1789416000000,"preClose":30.7033,"halted":0,"volume":181,"hourTrading":{"tag":"盘后","latestPrice":30.7033,"preClose":30.1889,"latestTime":"16:10 EDT","volume":6,"amount":181.1956,"timestamp":1789416603919,"change":0.5144,"changeRate":0.017039,"amplitude":0},"delay":0,"changeRate":-0.01675389941797782,"floatShares":720000,"shares":720000,"eps":0,"marketStatus":"Not Yet Opened","change":-0.5144,"latestTime":"09-14 16:00:00 EDT","open":30.7033,"high":30.1889,"low":30.1889,"amount":5464,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":30.7033,"sharesOutstanding":720000,"nav":30.745,"aum":22136250.3,"dividendRate":0.023697,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":30.7033,"preClose":30.1889,"latestTime":"16:10 EDT","volume":6,"amount":181.1956,"timestamp":1789416603919,"change":0.5144,"changeRate":0.017039,"amplitude":0},"volumeRatio":0.345684},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEMS\",,,,,undefined,":{"symbol":"MEMS","floatShares":720000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.345684,"shares":720000,"dividePrice":0.7154,"high":30.1889,"amplitude":0,"preClose":30.7033,"low":30.1889,"week52Low":24.6357,"pbRate":"--","week52High":32.565,"institutionHeld":0,"latestPrice":30.1889,"eps":0,"divideRate":0.023697,"volume":181,"delay":0,"ttmEps":0,"open":30.7033,"prevYearClose":25.545,"prevWeekClose":30.7033,"prevMonthClose":30.6997,"prevQuarterClose":31.7347,"fiveDayClose":31.3175,"twentyDayClose":30.9864,"sixtyDayClose":31.7629},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MEMS\",params:#limit:5,,,undefined,":[{"date":"2025-12-17","symbol":"MEMS","amount":0.71648,"announcedDate":"2025-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-17","defaultRemindTime":1765981800000,"name":"MATTHEWS EMERGING MARKETS DISCOVERY ACTIVE ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-22","payableDate":"2025-12-17","currency":"USD","dateTimestamp":1765947600000,"payDate":"2025-12-22"},{"date":"2024-12-18","symbol":"MEMS","amount":0.33495,"announcedDate":"2024-12-17","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-18","defaultRemindTime":1734532200000,"name":"MATTHEWS EMERGING MARKETS DISCOVERY ACTIVE ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-23","payableDate":"2024-12-18","currency":"USD","dateTimestamp":1734498000000,"payDate":"2024-12-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MEMS\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-18","recordDate":"2024-12-18","paymentDate":"2024-12-23","value":0.33495,"currency":"USD"},{"executeDate":"2025-12-17","recordDate":"2025-12-17","paymentDate":"2025-12-22","value":0.71648,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MEMS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MEMS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1131237440","title":"Two Ministries Unveil 30 Trillion Yuan Plan to Supercharge Electronics Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=1131237440","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131237440?lang=en_us&edition=fundamental","pubTime":"2026-09-15 11:31","pubTimestamp":1789443066,"startTime":"0","endTime":"0","summary":"The Ministry of Industry and Information Technology and the National Development and Reform Commission have jointly released the \"15th Five-Year Plan for the Development of the Electronic Information...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTXL","BK6092","BK6511","SMHU","LU2229751404.USD","SOXY","TEKX","BK4535","KOMP","MEMS","CHPY","SOXX","XSD","CHPS","PBOT","SMHX","SSG","BK4588","PSI","BK4585","SMH","TCHI","PNT","VGT","NBDS","MVPS","SOXQ","BK4139","CHAT","5RE.SI","SOXS","LU2089279066.USD","USD","SOXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667690666","title":"Legend Biotech Updates and Expands Cell Therapy Clinical Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2667690666","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667690666?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:35","pubTimestamp":1789389340,"startTime":"0","endTime":"0","summary":"Legend Biotech ( ($LEGN) ) has shared an update. Legend Biotech updated its clinical pipeline disclosure on September 14, 2026, outlining a broad p...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/legend-biotech-updates-and-expands-cell-therapy-clinical-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/legend-biotech-updates-and-expands-cell-therapy-clinical-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","XBI","BK4139","MEDI","BK4581","CANC","BK4505","LEGN","MEMS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666193528","title":"Legend Biotech : Barclays Cuts Target Price to $74 from $78","url":"https://stock-news.laohu8.com/highlight/detail?id=2666193528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666193528?lang=en_us&edition=fundamental","pubTime":"2026-09-11 17:36","pubTimestamp":1789119384,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nAZN4TJO57:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","BK4588","LEGN","CANC","BK4585","MEDI","MEMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666933645","title":"GenScript Unit Legend Biotech to Present Updated Long-Term Carvykti Cartitude-2 Data at IMS Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666933645","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666933645?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:08","pubTimestamp":1789042081,"startTime":"0","endTime":"0","summary":"GenScript unit Legend Biotech to present updated long-term CARVYKTI CARTITUDE-2 data at IMS meetingGenScript Biotech’s Legend Biotech unit flagged updated long-term data for CARVYKTI from the CARTITUD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL8Dx5yk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","NDAQ","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD","01548","BK1583","BK4505","IE00BQXX3C00.GBP","HK0000320223.HKD","MEMS","BCDF","CANC","IE00BN0W2T93.GBP","BK4112","IE00BGHQF748.EUR","MEDI","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK1576","BK4139","IE00BQXX3F31.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK1141","SG9999014021.USD","BK4585","HK0000306685.HKD","HK0000306701.USD","IE00B64PRP62.GBP","SG9999014039.USD","LEGN","LU0314104364.USD","HK0000320264.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664856297","title":"Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664856297","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664856297?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:00","pubTimestamp":1788264000,"startTime":"0","endTime":"0","summary":"BRIDGEWATER N.J., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354079/0/en/legend-biotech-to-participate-in-the-morgan-stanley-global-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","FBT","LU0128526141.USD","LU0029874061.USD","LEGN","CANC","BK4139","CNCR","BK4137","SYNB","LFSC","IBB","XBI","BK4505","GNOM","BK4585","MEMS","BK4581","XLV","LABU","TBXU","IBBQ","HCSG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664007603","title":"MEMSCAP lifts first-half profit 53% and pays inaugural dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2664007603","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664007603?lang=en_us&edition=fundamental","pubTime":"2026-09-01 01:07","pubTimestamp":1788196074,"startTime":"0","endTime":"0","summary":"MEMSCAP SA ( ($FR:MEMS) ) just unveiled an update. MEMSCAP reported a 13% rise in first-half 2026 revenue to 6.94 million euros, driven by broad-ba...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/memscap-lifts-first-half-profit-53-and-pays-inaugural-dividend?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/memscap-lifts-first-half-profit-53-and-pays-inaugural-dividend?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEMS","BK4585","VIG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662760494","title":"MEMSCAP to Host Investor Webcast on First‑Half 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760494","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662760494?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:14","pubTimestamp":1787724894,"startTime":"0","endTime":"0","summary":"An update from MEMSCAP SA ( ($FR:MEMS) ) is now available. MEMSCAP SA will publish its first‑half 2026 financial results after market close on Mond...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/memscap-to-host-investor-webcast-on-firsthalf-2026-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/memscap-to-host-investor-webcast-on-firsthalf-2026-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4181","BK4585","BK4588","BK4218","MEMS","HST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662663757","title":"Will Legend Biotech’s (LEGN) Move to Q2 Profitability Reshape Its Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2662663757","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662663757?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:31","pubTimestamp":1787689883,"startTime":"0","endTime":"0","summary":"Legend Biotech Corporation recently reported its second-quarter 2026 results, with revenue rising to US$387.5 million from US$255.1 million and net income turning to US$33.2 million from a net loss of US$125.4 million a year earlier.\nOver the first half of 2026, revenue increased to US$692.6 million while the company sharply reduced its net loss to US$21.1 million, highlighting a rapid improvement in profitability metrics.\nWith Legend Biotech’s latest quarter showing a shift to...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/will-legend-biotechs-legn-move-to-q2-profitability-reshape-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/will-legend-biotechs-legn-move-to-q2-profitability-reshape-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AGIX","AIPO","BK4581","QTOC","CHAT","BK4505","BK4139","LEGN","ARTY","MEMS","BK4585","CANC","VTHR","BK4588","XBI","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660444987","title":"Legend Biotech (LEGN) Turns Profitable In Q2, Is The Stock Cheap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660444987","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660444987?lang=en_us&edition=fundamental","pubTime":"2026-08-19 17:19","pubTimestamp":1787131188,"startTime":"0","endTime":"0","summary":"Legend Biotech (LEGN) drew fresh attention after reporting second quarter 2026 results, with revenue of US$387.5 million and net income of US$33.2 million, compared with a net loss a year earlier.\nSee our latest analysis for Legend Biotech.\nLegend Biotech’s latest earnings and leadership change in July have come against a mixed share price backdrop, with a 1-year total shareholder return that declined 38.5% and a 3-year total shareholder return that declined 68.3%. Meanwhile, the year-to-date...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-turns-profitable-in-q2-is-the-stock-chea","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-turns-profitable-in-q2-is-the-stock-chea","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","CANC","MEDI","BK4585","XBI","MEMS","LEGN","BK4581","BK4505","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660492462","title":"Legend Biotech Sets September 24, 2026 AGM With Expanded Equity Plan on Agenda","url":"https://stock-news.laohu8.com/highlight/detail?id=2660492462","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660492462?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:28","pubTimestamp":1787084916,"startTime":"0","endTime":"0","summary":"Legend Biotech ( ($LEGN) ) has issued an update. Legend Biotech has called its Annual General Meeting of shareholders for September 24, 2026, at it...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/legend-biotech-sets-september-24-2026-agm-with-expanded-equity-plan-on-agenda?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/legend-biotech-sets-september-24-2026-agm-with-expanded-equity-plan-on-agenda?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4195","BK4229","XBI","BK4585","MEDI","BK4139","BK4505","MEMS","BK4581","CANC","AGM","LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660494190","title":"Legend Biotech Seeks Shareholder OK to Add 19.1 Million Shares to RSU Plan Reserve","url":"https://stock-news.laohu8.com/highlight/detail?id=2660494190","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660494190?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:03","pubTimestamp":1787083388,"startTime":"0","endTime":"0","summary":"Legend Biotech seeks shareholder OK to add 19.1 million shares to RSU plan reserveLegend Biotech seeks shareholder approval to amend its 2020 restricted shares plan, adding 19,100,000 ordinary shares ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL37LWfk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BK4585","CANC","MEDI","MEMS","BK4588","LEGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660549416","title":"Legend Biotech Announces Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2660549416","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660549416?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:02","pubTimestamp":1787083332,"startTime":"0","endTime":"0","summary":"Legend Biotech announces annual general meetingLegend Biotech schedules its annual general meeting in Bridgewater, New Jersey on Sept. 24, 2026.Shareholders will receive the audited consolidated finan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL8s0gBD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4505","LEGN","MEDI","MEMS","BK4139","BK4588","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660897469","title":"How Legend Biotech’s Q2 Profitability Jump and Interim CEO Shift Will Impact Legend Biotech (LEGN) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2660897469","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660897469?lang=en_us&edition=fundamental","pubTime":"2026-08-18 16:27","pubTimestamp":1787041666,"startTime":"0","endTime":"0","summary":"Legend Biotech Corporation recently reported past second-quarter 2026 results, with revenue rising to US$387.5 million from US$255.1 million a year earlier and net income improving to US$33.2 million from a net loss of US$125.4 million, while the board also appointed Alan Bash as interim CEO effective July 24, 2026.\nAn interesting aspect of this report is that the company produced positive earnings per share of US$0.18 in the quarter, even though it still recorded a net loss of US$21.1...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/how-legend-biotechs-q2-profitability-jump-and-interim-ceo-sh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/how-legend-biotechs-q2-profitability-jump-and-interim-ceo-sh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XBI","BK4505","BK4588","VOTE","LEGN","BK4211","DECU","FEBU","BK4585","PMDE","VGFPF","MEMS","JOYT","BK4139","CANC","RGLO","MEDI","BK4581","GXDW","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659516785","title":"Celcuity Posts Narrower-than-Expected Loss as R&D Costs Decreased","url":"https://stock-news.laohu8.com/highlight/detail?id=2659516785","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659516785?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:17","pubTimestamp":1786652236,"startTime":"0","endTime":"0","summary":"Celcuity posts narrower-than-expected loss as R&D costs decreasedOverviewUS biotechnology firm's Q2 adjusted loss per share beat analyst expectationsQ2 adjusted net loss also beat analyst expectations","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A15A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4585","MEMS","CELC","CANC","BK4139","LEGN","OMER","BK4007","KURA","BK4588","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659151875","title":"CorMedix Beats Q2 Revenue Estimates on DefenCath Growth, Raises FY Adjusted Ebitda Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2659151875","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659151875?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:42","pubTimestamp":1786621337,"startTime":"0","endTime":"0","summary":"CorMedix beatsQ2 revenue estimates on DefenCath growth, raises FY adjusted EBITDA guidanceOverviewUS biopharma firm's Q2 revenue rose, beating analyst expectationsEPS for Q2 beat analyst expectationsC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0I7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CANC","MEDI","BK4585","CRMD","OMER","MEMS","LEGN","BK4505","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900195","title":"Oncology Device Maker RenovoRx's Q2 Revenue Surges, Raises FY Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900195","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900195?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:20","pubTimestamp":1786566051,"startTime":"0","endTime":"0","summary":"Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlookOverviewTargeted oncology device maker's Q2 2026 revenue rose 115% yr/yr to record $909,000Company raised full-year 2026 revenue gu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N44911Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4539","LEGN","BK4139","BK4563","MEMS","ICCM","RNXT","IMNM","BK4505","BK4588","MEDI","BK4082","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659194900","title":"MaxCyte Q2 Revenue Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659194900","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659194900?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:20","pubTimestamp":1786566040,"startTime":"0","endTime":"0","summary":"MaxCyte Q2 revenue beats estimatesOverviewUS cell engineering platform's Q2 revenue fell 15% yr/yr but beat analyst expectationsQ2 adjusted EBITDA loss was larger than analyst consensusCompany repurch","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N44911J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","BK4121","BK4139","BK4505","MXCT","BK4585","MEMS","BK4539","PROK","LEGN","QTRX","BK4588","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659008519","title":"Kura Oncology Q2 Product Revenue Rises 57% on Komzifti Uptake","url":"https://stock-news.laohu8.com/highlight/detail?id=2659008519","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659008519?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:11","pubTimestamp":1786565467,"startTime":"0","endTime":"0","summary":"Kura Oncology Q2 product revenue rises 57% on KOMZIFTI uptakeOverviewU.S. cancer drugmaker's Q2 net product revenue rose 57% from prior qtr on KOMZIFTI uptakeTotal Q2 revenue grew yr/yr, driven by pro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N44910S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","KURA","BK4139","BK4505","BK4007","BK4585","MEMS","LQDA","LEGN","BK4588","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907385","title":"Sector Update: Healthcare Stocks Advance Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907385","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907385?lang=en_us&edition=fundamental","pubTime":"2026-08-13 03:58","pubTimestamp":1786564721,"startTime":"0","endTime":"0","summary":"Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and the State Street Health Care Select Sector SPDR ETF  adding 0.3%.The iShares Biotechnology ETF  rose 0.5%.In corporate news, Merck  shares rose 2.4% after Daiwa upgraded the stock to outperform from neutral and raised its price target to $143 per share from $120.Cencora  said that certain Walgreens volume that was being serviced by the company, separate from the prime vendor agreement, has started moving outside the company from July 1. Meanwhile, Cencora said its prime vendor agreement remains unchanged and accounts for the majority of its business with Walgreens. Cencora shares fell past 5%.Legend Biotech  could see pressures from competition and recent leadership change, potentially weighing on Carvykti myeloma therapy strategy, Oppenheimer said. It downgraded Legend to perform from outperform. Shares fell 5.2%.Definium Therapeutics  shares rose 5% after the firm said its phase 3 trial","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2491049909.HKD","SG9999002224.SGD","LU1162221912.USD","LU2112291526.USD","LU0289739699.SGD","MEMS","LU1037948897.HKD","LU2125154935.USD","LU0689626769.HKD","LU0208291251.USD","LU0320765489.SGD","LU1989772840.SGD","XBI","FTXH","IHE","PPH","LU1814569148.SGD","IE00BLSP4452.SGD","MEDI","SG9999014575.USD","LU0122379950.USD","LU1093756168.USD","LU1983299246.USD","LU2357627491.SGD","LU1066051811.HKD","IE00B4R5TH58.HKD","LU2361044865.SGD","IE0009355771.USD","LU0965509101.SGD","LEGN","LU0203345920.USD","LU1974910355.USD","LU1201861249.SGD","LU0823416689.USD","IE00BN8TJ469.HKD","SG9999004303.SGD","BK4559","SG9999014559.SGD","LU0980610538.SGD","IE00B1BXHZ80.USD","IE0002141913.USD","IE00BBT3K403.USD","LU1941712264.USD","FHLC","SG9999001176.USD","COR","LU1084165304.USD","BK4516","LU0130517989.USD","LU1066051225.USD","LU1585245621.USD","LU0124676726.USD","BK4084","SG9999014567.USD","CANC","LU1934455194.USD","LU0006306889.USD","BK4533","LU0265550946.USD","SG9999002232.USD","LU1023059063.AUD","LU0868494617.USD","LU1066053197.SGD","LU0098860793.USD","LU0238689110.USD","LU0965508806.USD","LU1699723380.USD","LU2237957902.USD","LU2361045086.USD","IE00BSNM7G36.USD","LU0942090050.USD","IE00BLSP4239.USD","LU2125154778.USD","GDOC","LU0985320562.USD","LU2360032135.SGD","SGXZ57979304.SGD","LU0130102774.USD","BK4550","LU2237957811.SGD","BK4007","LU1066051498.USD","LU2361044949.HKD","LU0477156953.USD","LU2125909593.SGD","LU2106854487.HKD","LU0203347892.USD","MRK","LU1941712348.USD","LU0106261372.USD","LU0965509283.SGD","LU1989771016.USD","LU1057294990.SGD","LU1119994496.HKD","LU1929549753.HKD","IXJ","BK4588","VHT","LU0965509010.AUD","LU2433249047.HKD","LU1035773651.USD","LU0320765646.SGD","LU2468319806.SGD","LU1093756325.SGD","LU2023250504.SGD","LU0058720904.USD","LU2491050154.USD","LU2324357040.USD","LU1069347547.HKD","LU0432979614.USD","LU0648001328.SGD","LU1291159041.SGD","BK4585","BK4175","LU1917777945.USD","BK4581","LABU","IYH","LU1934455277.USD","LU0859254822.USD","SG9999015358.SGD","XLV","LU1923622614.USD","LU1934455863.HKD","LU1061106388.HKD","LU1116320737.USD","LU0234572021.USD","BK4505","LU1261432733.SGD","LU0211331839.USD","LU2089984988.USD","LU0868494708.USD","SG9999014542.SGD","LU1989772923.USD","JDOC","BK4534","RXL","BMED","LU1116320901.HKD","LU1571399168.USD","LU2491050071.SGD","LU1430594728.SGD","TRUH","PAWZ","LU0070302665.USD","SG9999013999.USD","IBB","LU2125909247.SGD","SGXZ23171101.USD","IE00BFTCPJ56.SGD","SG9999001176.SGD","IE00BJJMRZ35.SGD","DFTX","BK4139","HRTS","IE00B2B36J28.USD","IE000M9KFDE8.USD","LU2461242641.AUD","SG9999001440.SGD","SG9999015341.SGD","LU0266013472.USD","LU1037948541.HKD","LU0861579265.USD","LU2023250843.SGD","BK4529","LU0265550359.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658909519","title":"Legend Biotech Could See Pressures From Competition, CEO Transition, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2658909519","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658909519?lang=en_us&edition=fundamental","pubTime":"2026-08-12 23:58","pubTimestamp":1786550316,"startTime":"0","endTime":"0","summary":"Legend Biotech  could see pressures from competition and its recent leadership change, potentially weighing on its Carvykti myeloma therapy strategy, Oppenheimer said in a Wednesday note.Chief Executive Ying Huang resigned from the company in July and his departure raised concerns over strategies as Anito-cel nears potential approval and commercialization as a competing myeloma treatment, the investment firm said.Anito-cel's approval could pressure Legend Biotech's stock and Carvykti's near-term growth, but Oppenheimer noted that it continues to expect Carvykti to corner a majority of the market share in multiple myeloma.Carvykti sales could still peak at about $5 billion, but its near-term position could depend on the new CEO's strategic vision, the brokerage said.Oppenheimer downgraded Legend Biotech to perform from outperform and adjusted the price target to $40 from $75.Price: 20.66, Change: -1.17, Percent Change: -5.36","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","XBI","BK4585","BK4127","BK4505","CANC","BK4581","MEMS","OPY","BK4139","MEDI","LEGN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":60,"code":"91000000","status":"200"}]}}